SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis.

Published on Dec 4, 2019in Therapeutic Advances in Gastroenterology3.52
· DOI :10.1177/1756284819891081
João Gonçalves34
Estimated H-index: 34
(University of Lisbon),
Gihyun Myung2
Estimated H-index: 2
(Samsung)
+ 2 AuthorsJeehoon Ghil9
Estimated H-index: 9
(Samsung)
Sources
Abstract
Background:The primary objective of this study was to analyze the cross-reactivity of antidrug antibodies to reference adalimumab (ADL) and SB5 (adalimumab biosimilar) in patients with inflammatory...
Download
📖 Papers frequently viewed together
2 Citations
References25
Newest
#1Akos Ilias (Semmelweis University)H-Index: 3
#2Kata Szántó (University of Szeged)H-Index: 4
Last. Peter L. Lakatos (McGill University)H-Index: 84
view all 13 authors...
Background & Aims There is evidence that it is safe and effective for patients with inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original infliximab drug to a biosimilar, but little is known about outcomes of reverse switches and/or multiple switches. We aimed to evaluate the effects of a reverse switch (from a biosimilar to Remicade) in a real-life cohort. Methods We performed a prospective observational study of 174 unselected and consecutive patients with IBD (...
15 CitationsSource
#1Nikolas Plevris (Western General Hospital)H-Index: 7
#2Gareth R. Jones (Western General Hospital)H-Index: 7
Last. Charlie W. Lees (Western General Hospital)H-Index: 49
view all 14 authors...
Background Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn’s disease.
18 CitationsSource
#1Byong Duk Ye (UOU: University of Ulsan)H-Index: 37
#2Marina PesegovaH-Index: 4
Last. Young-Ho Kim (SMC: Samsung Medical Center)H-Index: 29
view all 20 authors...
Summary Background The infliximab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns about such indication extrapolation have been expressed. This study investigated whether CT-P13 is non-inferior to infliximab in patients with Crohn's disease who were naive to biological therapy. Methods In this randomised, multicentre, double-blind, phase 3 non-inferiority study, we...
71 CitationsSource
#1G. L. GollH-Index: 6
#2K.K. Jørgensen (Ahus: Akershus University Hospital)H-Index: 6
Last. Tore K KvienH-Index: 116
view all 48 authors...
BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment with infliximab originator. The NOR-SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT-P13 throughout the 78-week study period (maintenance group) versus patients switched to CT-P13 at week 52 (switch group). T...
50 CitationsSource
#2José L. PablosH-Index: 44
#3Karel PavelkaH-Index: 78
Last. Eswar Krishnan (Amgen)H-Index: 1
view all 8 authors...
ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 w...
16 CitationsSource
#1JongAh Joanne Lee (Samsung)H-Index: 3
#2Junmo Yang (Samsung)H-Index: 1
Last. Jiyoon Yang (Samsung)H-Index: 1
view all 6 authors...
Abstract A biosimilar is a biological medicinal product that is highly similar to an authorized biological product in terms of quality, biological activity, safety and efficacy. SB5 was developed by Samsung Bioepis as a biosimilar referencing adalimumab, and was authorized by the European Commission (EC) in August 2017 (Imraldi®). Extensive characterization studies were performed to demonstrate functional similarity of SB5 to reference adalimumab (Humira®, AbbVie Inc. and AbbVie Deutschland GmbH...
12 CitationsSource
#1Marjorie ArgolloH-Index: 11
#2Gionata FiorinoH-Index: 51
Last. Silvio DaneseH-Index: 100
view all 9 authors...
INTRODUCTION: Biosimilars present a considerable potential to reduce costs related to clinical management allowing health-care providers to reinvest this money, leading to a wider access to an effective biological treatment with monoclonal antibodies (mAb). Infliximab biosimilars have already been incorporated in daily clinical practice and are currently used in all indications for which the reference product (RP) was approved. Areas covered: In the next few years, also adalimumab biosimilars wi...
4 CitationsSource
#1Nayoung Lee (Samsung)H-Index: 3
#2JongAh Joanne Lee (Samsung)H-Index: 3
Last. Gwangmin Park (Samsung)H-Index: 1
view all 9 authors...
ABSTRACTBiosimilars are biologic products that are highly similar to a licensed reference product in terms of quality, safety, and efficacy. SB5 is a biosimilar of Humira® (adalimumab) developed by...
18 CitationsSource
#3Eleonora A M Festen (UMCG: University Medical Center Groningen)H-Index: 19
Introduction TNF-α-neutralizing antibodies, such as infliximab (IFX) and adalimumab (ADA), are effective in the treatment of inflammatory bowel diseases (IBD), but they are expensive and become ineffective when patients develop anti-IFX or anti-ADA antibodies (ATI and ATA, respectively). Second-generation anti-TNF-α antibodies, such as Golimumab, Etanercept, Certolizumab-pegol and IFX biosimilars, may solve these issues. Aim To determine the neutralizing capacity of first- and second generation ...
3 CitationsSource
#1Alexandre Jentzer (French Institute of Health and Medical Research)H-Index: 1
#2Anne-Emmanuelle Berger (French Institute of Health and Medical Research)H-Index: 5
Last. Stéphane Paul (French Institute of Health and Medical Research)H-Index: 33
view all 6 authors...
BACKGROUND: SB2, an infliximab (IFX) biosimilar to the reference infliximab (R.I.) product (Remicade), received approval in the European Union for all IFX indications. Many decision algorithms based on the measurement of IFX trough levels and antibodies to infliximab are being increasingly used to optimize IFX treatment. The aim of our study was to evaluate whether the biosimilar SB2 could be efficiently monitored using the LISA-TRACKER IFX and anti-IFX assays developed by Theradiag (Croissy Bea...
5 CitationsSource
Cited By6
Newest
#1Krzysztof BonekH-Index: 3
#2Leszek RoszkowskiH-Index: 1
Last. Marzena CiechomskaH-Index: 16
view all 5 authors...
Rheumatoid arthritis (RA) affects around 1.2% of the adult population. RA is one of the main reasons for work disability and premature retirement, thus substantially increasing social and economic burden. Biological disease-modifying antirheumatic drugs (bDMARDs) were shown to be an effective therapy especially in those rheumatoid arthritis (RA) patients, who did not adequately respond to conventional synthetic DMARD therapy. However, despite the proven efficacy, the high cost of the therapy res...
1 CitationsSource
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Gerben FerwerdaH-Index: 30
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 4 authors...
Recently, ustekinumab has been approved for the treatment of Crohn's disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present three patients with therapy-refractory Crohn's disease, who experienced an immediate infusion reaction to intravenous administration of ustekinumab. In two of these patients a subsequent reaction to subcutaneous injections occurred. Clinical features and pathophysiology are discussed.
1 CitationsSource
Source
#1Virginia Solitano (Humanitas University)H-Index: 2
#2Ferdinando D'Amico (Humanitas University)H-Index: 14
Last. Silvio Danese (Humanitas University)H-Index: 15
view all 5 authors...
After patents’ expiration of biological originators, several biosimilars of infliximab and adalimumab have been authorized. The approval is based on data extrapolated from other indications for whi...
3 CitationsSource
#1Sang Hyoung Park (UOU: University of Ulsan)H-Index: 27
#2Jae Cheol Park (UOU: University of Ulsan)H-Index: 1
Last. Edward V. Loftus (Mayo Clinic)H-Index: 114
view all 5 authors...
The inflammatory bowel diseases (IBD), which consist of Crohn’s disease and ulcerative colitis, are chronic, incurable immune-mediated inflammatory disorders of the intestine. As IBD incidence continues to increase globally and its mortality is low, prevalent cases of IBD are rapidly increasing, thereby leading to a substantial increase in health care costs. Although the introduction of biologic agents for IBD management has revolutionized the armamentarium of IBD therapy, the high cost of this...
4 CitationsSource
#1Alexandre Jentzer (French Institute of Health and Medical Research)H-Index: 1
#2Anne-Emmanuelle Berger (French Institute of Health and Medical Research)H-Index: 5
Last. Stéphane Paul (French Institute of Health and Medical Research)H-Index: 33
view all 6 authors...
BACKGROUND: SB2, an infliximab (IFX) biosimilar to the reference infliximab (R.I.) product (Remicade), received approval in the European Union for all IFX indications. Many decision algorithms based on the measurement of IFX trough levels and antibodies to infliximab are being increasingly used to optimize IFX treatment. The aim of our study was to evaluate whether the biosimilar SB2 could be efficiently monitored using the LISA-TRACKER IFX and anti-IFX assays developed by Theradiag (Croissy Bea...
5 CitationsSource